While Akero Therapeutics Inc has underperformed by -0.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AKRO fell by -51.21%, with highs and lows ranging from $58.38 to $11.25, whereas the simple moving average fell by -21.58% in the last 200 days.
On April 22, 2024, BofA Securities started tracking Akero Therapeutics Inc (NASDAQ: AKRO) recommending Neutral. A report published by Cantor Fitzgerald on September 19, 2023, Initiated its previous ‘Overweight’ rating for AKRO. UBS also rated AKRO shares as ‘Buy’, setting a target price of $83 on the company’s shares in an initiating report dated August 28, 2023. Morgan Stanley January 27, 2023d the rating to Overweight on January 27, 2023, and set its price target from $40 to $65. Evercore ISI September 14, 2022d its ‘In-line’ rating to ‘Outperform’ for AKRO, as published in its report on September 14, 2022. Morgan Stanley’s report from October 19, 2021 suggests a price prediction of $27 for AKRO shares, giving the stock a ‘Equal-Weight’ rating. BofA Securities also rated the stock as ‘Buy’.
Analysis of Akero Therapeutics Inc (AKRO)
In order to gain a clear picture of Akero Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -35.22% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 29.27, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.34M can be a very valuable indicator of volatility for AKRO stock. On a monthly basis, the volatility of the stock is set at 5.11%, whereas on a weekly basis, it is put at 5.88%, with a gain of 10.71% over the past seven days. Furthermore, long-term investors anticipate a median target price of $48.89, showing growth from the present price of $22.02, which can serve as yet another indication of whether AKRO is worth investing in or should be passed over.
How Do You Analyze Akero Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.42%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 82.66% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AKRO shares are owned by institutional investors to the tune of 82.66% at present.
